# Syntis Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/syntis-bio

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.syntis.bio
- Total disclosed funding: $29M
- Latest round: Series A (Jun 17, 2025)
- Investors on record: 10

## About

Syntis Bio, Inc. is a biotechnology firm based in the US specializing in innovative oral therapies aimed at tackling critical healthcare challenges like obesity and diabetes through unique drug absorption technologies.Syntis Bio, Inc. is engaged in the development of oral therapies that utilize the small intestine's biology to address healthcare issues. Founded in 2024 and headquartered in Boston, US, the company has raised a total of USD 33.00 mn, with its most recent funding round being a Series A in July 2025 led by Cerberus Capital Management. The funding will support its ongoing research initiatives, particularly the development of its flagship product, SYNT-101, which focuses on obesity treatment. The company has achieved 3 deals to date.Syntis Bio specializes in developing innovative oral therapies that leverage the unique biology of the small intestine to address pivotal healthcare challenges, particularly in the realms of obesity, diabetes, and rare genetic disorders. The company's primary product offerings focus on drug candidates designed for metabolic control, digestion, and enhanced drug absorption, particularly targeting obesity. These therapies are aimed at North America and Europe, catering to healthcare providers and patients seeking advanced treatment options.Syntis Bio's revenue model is based on partnerships and direct sales of its oral therapies to healthcare providers and institutions. Engaging in B2B transactions, the company collaborates with hospitals and clinics to administer its drug candidates. Recently, Syntis Bio secured USD 33.00 mn in funding to support the development and commercialization of its products, particularly focusing on its leading candidate, SYNT-101, which addresses obesity treatment. The revenue strategy is further enhanced through research and market engagement efforts.Syntis Bio plans to leverage its recent funding of USD 5.00 mn from The National Institutes of Health, received in July 2025, to advance the SYNT platform, particularly the SYNT-101 obesity program. The company is also targeting expansion into additional markets within North America and Europe to reach more patients facing obesity and related health issues. This strategic growth will facilitate the introduction of new products and enhance the accessibility of its therapies.

## Funding rounds

- Series A, Jun 17, 2025, $25M — Cerberus Capital Management, WOORI Venture Partners, W.R. Berkley, BOLD Capital Partners, Safar Partners, Colorcon Ventures, Portal Innovations, Mansueto Office, Apollo Labs
- Seed, Jan 17, 2023, $4.2M — Touchdown Ventures, BOLD Capital Partners, Safar Partners, Colorcon Ventures, Portal Innovations

## Investors

- Touchdown Ventures (https://capitalatlas.ai/funds/touchdown-ventures) — Seed
- BOLD Capital Partners (https://capitalatlas.ai/funds/bold-capital-partners) — Seed, Series A
- Safar Partners (https://capitalatlas.ai/funds/safar-partners) — Seed, Series A
- Colorcon Ventures (https://capitalatlas.ai/funds/colorcon-ventures) — Seed, Series A
- Portal Innovations (https://capitalatlas.ai/funds/portal-innovations) — Seed, Series A
- Cerberus Capital Management (https://capitalatlas.ai/funds/cerberus-capital-management) — Series A
- WOORI Venture Partners (https://capitalatlas.ai/funds/woori-venture-partners) — Series A
- W.R. Berkley (https://capitalatlas.ai/funds/w-r-berkley) — Series A
- Mansueto Office — Series A
- Apollo Labs — Series A